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Abstract
Background: TSC2-deficient cells can proliferate in the lungs, kidneys, and other organs causing devastating progressive
multisystem disorders such as lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC). Preclinical models
utilizing LAM patient-derived cells have been difficult to establish. We developed a novel animal model system to study the
molecular mechanisms of TSC/LAM pathogenesis and tumorigenesis and provide a platform for drug testing.
Methods and Findings: TSC2-deficient human cells, derived from the angiomyolipoma of a LAM patient, were engineered
to co-express both sodium-iodide symporter (NIS) and green fluorescent protein (GFP). Cells were inoculated
intraparenchymally, intravenously, or intratracheally into athymic NCr nu/nu mice and cells were tracked and quantified
using single photon emission computed tomography (SPECT) and computed tomography (CT). Surprisingly, TSC2-deficient
cells administered intratracheally resulted in rapid dissemination to lymph node basins throughout the body, and
histopathological changes in the lung consistent with LAM. Estrogen was found to be permissive for tumor growth and
dissemination. Rapamycin inhibited tumor growth, but tumors regrew after the drug treatment was withdrawn.
Conclusions: We generated homogeneous NIS/GFP co-expressing TSC2-deficient, patient-derived cells that can proliferate
and migrate in vivo after intratracheal instillation. Although the animal model we describe has some limitations, we
demonstrate that systemic tumors formed from TSC2-deficient cells can be monitored and quantified noninvasively over
time using SPECT/CT, thus providing a much needed model system for in vivo drug testing and mechanistic studies of TSC2-
deficient cells and their related clinical syndromes.
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Introduction
Tuberous sclerosis complex (TSC) is a tumor suppressor gene
syndrome and autosomal-dominant genetic disease with a
prevalence of 1 in 6,000 births and a 95% penetrance [1,2].
The characteristic manifestations of TSC include cortical tubers,
subependymal giant cell astrocytomas, cardiac rhabdomyomas,
renal angiomyolipoma (AML), and life-threatening pulmonary
lymphangioleiomyomatosis (LAM) [3].
LAM is a rare disease affecting primarily women of childbearing
age. Abnormal proliferation of smooth muscle-like cells (called
LAM cells) leads to distortion of lung architecture, cystic lung
destruction, and enlargement of the thoracic and abdominal axial
lymphatics, rarely resulting in lymphedema [4,5]. LAM occurs
sporadically and is also found in 30% to 40% of adult female TSC
patients [6]. Approximately two-thirds of women with sporadic
LAM also have renal AML.
TSC and LAM are caused by mutations of one of two tumor
suppressor genes,TSC1andTSC2,locatedonchromosome9q34or
chromosome 16p13, respectively [7,8,9]. The heterodimer of
hamartin (encoded by TSC1) and tuberin (TSC2) suppress the
mammalian target of rapamycin (mTOR), a major regulator of cell
cycleprogression,cellgrowth,andproliferation[10,11].mTORisa
serine-threonine kinase that receives input from various signaling
pathways to activate translation, thus increasing cell proliferation
and growth [12]. TSC2 loss or mutation leads to disruption of the
tuberin-hamartin heterodimer. Additionally, dysregulation of coor-
dinated mTOR and PI3K signaling contributes to tumorigenesis, a
common characteristic of LAM [13,14,15].
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38589LAM and AML are comprised of cells with TSC1 or TSC2
mutations, which permits investigators to discriminate between
‘‘two hit’’ cells [16,17] and adjacent cells or matrix. Lung LAM
cells develop as nodular structures with spindle-shaped and
epithelioid cells, which are immunophenotypically distinct.
Although they both express alpha-smooth muscle actin (a-SMA),
epithelioid cells often harbor melanoma markers such as gp100,
MART-1 [18]. TSC2-deficient cells are histologically benign, but
have the potential to metastasize in vivo [19,20,21]. Several TSC2-
deficient or null cells have been isolated from AML patients
previously, but isolating and establishing sustained cultures of
AML and LAM cells has been challenging [22,23,24], in part
because of the heterogeneity of LAM nodules [25]. Nevertheless,
the need to obtain an understanding of how existing cell lines
behave in vivo is of paramount importance.
There are several imaging modalities that can be used to monitor
tumormetastasisandproliferationinvivo,includingopticalimaging,
positron emission tomography (PET), single photon emission
computed tomography (SPECT), X-ray computed tomography
(CT), and magnetic resonance imaging (MRI). A variety of gene
reporter systems have been used to enhance the sensitivity and
specificityfortrackingcellsinvivowiththesemodalities.Thesodium-
iodidesymporter(NIS),amediatorofiodideanionuptake,ismainly
expressed on the basolateral membrane of thyroid follicular cells in
the thyroid gland and superficial mucin-secreting epithelial cells in
thestomach[26,27].Thus,ectopicexpressionofNISonanyothercell
type permits sensitive detection by using a radiotracer that is
recognized by the symporter. Fortunately, in addition to the iodide
anion, NIS also mediates transport of the pertechnetate anion
99mTcO4
-,providingsafe,nonvolatile,inexpensive,andnoninvasive
tracking usingSPECT [28,29].
In this study, we engineered homogeneous TSC2-deficient
LAM patient-derived cells that co-express NIS and GFP and
studied their pattern of proliferation and dissemination in vivo, and
their response to hormones and drugs.
Methods
Plasmids and Cell Lines
621-101 cells were previously isolated from a renal angiomyoli-
poma of a sporadic LAM patient and immortalized, as described
previously [30,31]. Generation and use of the 621-101 cells was
approved by the Institutional Review Board at Fox Chase Cancer
Center in Philadelphia, and written informed consent was obtained
from the participant in the study. 621-101 cells were cultured in a
50/50 mixture of DMEM/F12 (Invitrogen, Carlsbad, CA) supple-
mented with epidermal growth factor (EGF, 10 ng/ml; Sigma-
Aldrich, St. Louis, MO), 200-nM hydrocortisone (Sigma-Aldrich),
25-mg/ml insulin (Sigma-Aldrich), 50-nM sodium selenite (Sigma-
Aldrich), 10-mg/ml transferrin (Sigma-Aldrich), 1.6-mM ferrous
sulfate (Sigma-Aldrich), and 15% fetal bovine serum (Gemini) as
described by Arbiser et al. [22].
Human solute carrier family member 5 (SLC5A5; sodium-iodide
symporter) was purchased from Open Biosystems (Huntsville, AL).
The verified cDNA of human NIS was cloned into the pBMN-
GFP retroviral plasmid (Orbigen Inc., San Diego, CA). The
detailed method for high titer virus production is described in the
Methods S1. The freshly collected supernatants containing Retro-
NIS/GFP viruses were used to infect 621-101 cells under selection
with 2-mg/mL puromycin. After subcloning, the chosen puromy-
cin-resistant cell line was designated 621-327 and multiple vials
were frozen at the time of establishment. A single vial was
expanded no more than 15 passages after thawing prior to
inoculation into mice.
HEK293T cells (American Type Culture Collection, Manassas,
VA) were grown with DMEM medium containing 10% fetal
bovine serum, penicillin (100 U/mL), streptomycin (100 mg/mL),
and 2-mM L-glutamine (Mediatech Inc., Manassas, VA).
Immunofluorescence Microscopy and
Immunohistochemistry
Immunofluorescence analysis of NIS expression in cells and
tissues was performed using rabbit anti-NIS (1:50; Abcam,
Cambridge, MA) and rabbit monoclonal anti-TSC2, specifically
recognizing C-terminal region of human TSC2/tuberin (1:50;
Millipore, Temecula, CA), respectively. Cy3 (Jackson ImmunoR-
esearch, West Grove, PA) goat anti-rabbit IgG (H+L) (1:200) was
used as a secondary antibody. For immunohistochemistry, thin
sections of frozen samples were blocked with 5% goat serum in
PBS-T and incubated with rabbit anti-Ki-67 (1:50, Santa Cruz),
rabbit anti-NIS (1:50, Abcam) or rabbit anti-GFP polyclonal
antibody (1:200; Abcam), respectively. Alexa Fluor 680 (Invitro-
gen, Carlsbad, CA) goat anti-rabbit IgG (H+L) (1:200) was used as
a secondary antibody. TUNEL staining was performed using a
TACS
H 2 TdT-DAB In Situ Apoptosis Detection kit according to
the manufacturer’s instructions (Trevigen, Inc., Gaithersburg,
MD). Detailed methods are described in Methods S1.
Immunoblotting
Cells were lysed with 0.5 ml of M-PER
TM (Pierce, Rockford,
IL) mammalian protein extraction reagent. Protein concentration
was quantified using a Bradford kit and normalized to 20 mg per
lane. Samples were boiled for 5 min and separated on a 4% to
20% Tris-Tricine SDS-PAGE gel. After transfer to PVDF
membranes (PerkinElmer Life Science, Boston, MA) and blocking
at room temperature for 2 h with 5% dried milk, membranes were
incubated overnight at 4uC with antibodies against tuberin (C-20)
(1:1000; Santa Cruz), phospho-Akt (1:1000; Cell Signaling), Akt
(1:1000; Santa Cruz), phospho-S6 (1:1000; Cell Signaling), NIS
(1:1000; Abcam), GFP (1:1000; Abcam) or b-actin (Cell Signaling).
Membranes were washed, incubated for 1 h with the appropriate
secondary antibodies (1:10000; Thermo Scientific, Rockford, IL),
and quantified using SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientific).
In vitro Radiotracer
99mTcO4 Uptake
621-327and621-101cellswereculturedin6-cmdishesuntil80%
confluent and in log-phase of growth. Cells were washed once with
5 ml of prewarmed PBS before adding 250-mCi 99
mTc-pertechne-
tate in 3-ml PBS. Cells were incubated at 37uC for 1 h. After
incubation, the cells were washed once with PBS before performing
SPECT/CT to quantitate
99mTc-pertechnetate uptake.
TSC2-deficient Cell Dissemination and Proliferation in
Animal Models
Animal studies were performed in accordance with the approved
institutional protocol #155–2008 by the Institutional Animal Care
and Use Committee (IACUC) of Beth Israel Deaconess Medical
Center. Female and male athymic NCr nu/nu mice were purchased
from Taconic Farms (Hudson, NY). At the time of tumor cell
inoculation, mice averaged 5 to 6 weeks of age and weighed 22 g
63 g. For tumor cell inoculation, anesthesia was induced using
intraperitoneal (IP) injection of a mixture of 50-mg/kg ketamine
hydrochloride (Ketaject; Phoenix Pharmaceutical Inc., St. Joseph,
MO) and 5-mg/kg xylazine hydrochloride (Bayer Corp., Shawnee
Mission, KS). Approximately 10 million TSC2-deficient cells in
100 mLPBSwereadministratedintofemalemicevia(1)intravenous
SPECT/CT Model of LAM/TSC
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intratracheally using a 1cc syringe and 20-gauge 1.5-inch needle.
Detailed methods are described in Methods S1.
SPECT/CT Imaging of TSC2-deficient Tumors in Mice
TSC2-deficient tumors were assessed on the days indicated
using micro SPECT/CT. Two hours prior to imaging, animals
were anesthetized with 2% isoflurane/balance O2 and 500 mCi of
99mTcO4
- in 50-ml saline, which was injected intravenously. For
imaging, animals were anesthetized with 2% isoflurane/balance
O2 and scanned on a NanoSPECT/CT (Bioscan Inc., Washing-
ton, DC). Quantitation of tumor volume, and
99mTc uptake was
performed using InVivoScope software (Bioscan Inc., Washington,
DC). All imaging parameters are provided in Methods S1. Six to
eight tumors in 1 mouse were quantified, and the average served
as the output for statistical analysis.
Identification of TSC2 Mutations in Tumor Cells
TSC2-deficient tumors and organs were excised immediately
after animal sacrifice, embedded in Tissue-Tek O.C.T, flash-
frozen in LN2, and stored at 280uC until use. Genomic DNA was
isolated using a QIAamp DNA Mini Kit (Qiagen GmbH, Hilden,
Germany). For a positive control, genomic DNA was isolated from
621-101 or 621-327 cells. Genomic DNA from tumor-bearing
mice was used as a template to amplify exon 17 of the TSC2 gene.
The PCR-amplified exon 17 products were verified by DNA
sequencing. The detailed methods and primer sequences are
described in Methods S1.
Hormone and Drug Treatment Studies
For the hormone and sex study, male and female mice (n=3
per group) were implanted with 17ß-Estradiol pellets (0.18 mg/
pellet, 90 day release; Innovative Research, Sarasota, FL) or
control placebo pellets subcutaneously. The release rate was 1.5 to
2 mg daily. Mice were inoculated with tumor cells by intratracheal
instillation 7 to 10 days after pellet implantation. Radiotracer
uptake of tumors was measured using SPECT/CT every 2 weeks
after tumor cell inoculation. Prior to rapamycin (Santa Cruz
Biotechnology, Santa Cruz, CA) treatment, 2 groups of n=4 mice
each were created so that baseline tumor size and number were
equal 2 weeks post-tumor cell inoculation. One group was treated
with 100 mL of intraperitoneal rapamycin (8 mg/kg) injection
Figure 1. Generation and characterization of in vivo trackable TSC2-deficient cells. A. Expression cassettes of adenoviral (Ad-NIS/GFP) and
retroviral (Retro-NIS/GFP) vectors. CMV = cytomegalovirus promoter, NIS = sodium-iodide symporter, LITR = left-handed inverted terminal repeat,
RITR = right-handed inverted terminal repeat, GFP = green fluorescent protein, DE1, DE3= E1 and E3 deletions of adenovirus type 5 (Ad5) backbone
sequence, 59 LTR=59 long terminal repeat, w signal = virus packing signal, IRES = internal ribosome entry site, 39 LTR =39 long terminal repeat. B.
In vitro uptake of
99mTc-pertechnetate and GFP fluorescence in stable Retro-NIS2/GFP-expressing 621-327 cells (top row) and control 621-101 cells
(bottom row). Scale bar=6 mm. C. Immunofluorescent detection of GFP, NIS, and tuberin in TSC2-deficient 621-327 cells (top row), control 621-101
cells (middle row), and HeLa cells (bottom row). GFP fluorescence (2nd column), staining with primary anti-NIS specific antibody (3rd column) or anti-
tuberin antibody (right column) with secondary Cy3 antibody conjugates is shown along with phase contrast (left column). Scale bar=50 mm. D.
Western blot analysis of TSC2-expressing HEK293T control cells, and TSC2-deficient 621-101 cells and 621-327 cells, using antibodies to key signaling
proteins, NIS, and GFP. A beta actin loading control is also shown, as are long exposure times (long exp.) for tuberin and hamartin.
doi:10.1371/journal.pone.0038589.g001
SPECT/CT Model of LAM/TSC
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control group received 100 mL of the vehicle (PBS). Tumor growth
was quantified every other week as described above using SPECT.
Results
Establishment of an in vivo Trackable TSC2-deficient Cell
Line Co-expressing NIS and GFP
Adenoviral and retroviral gene delivery vectors (Figure 1A) were
used to deliver NIS and GFP genes into human cell line 621-101,
which was derived from a LAM-associated angiomyolipoma. After
initial proof of principle using adenovirus expression, retrovirus
expression was used exclusively. Retrovirus-transduced NIS/GFP
cells were selected and subcloned. A stable cell line designated 621-
327 was obtained. Clonal 621-327 cells were adapted to grow in
DMEM/F12 medium supplemented with 15% fetal bovine serum,
penicillin (100 U/mL), and streptomycin (100 mg/mL). No EGF or
other additives were added into the cell culture medium. 621-327
cells characterized by simultaneous expression of GFP and NIS are
capableofmediatingradiotracer
99mTcO4
-uptake,whilethecontrol
621-101 cellswere not (Figure1B). Aftercontinuoussubculturing of
a vialofthese frozen cellsfor over 6months, the tested 621-327cells
showed stable high-level expression of functional NIS and GFP, but
low-level expression of tuberin (Figure 1C), and retained homoge-
neous morphology.
Characterization of TSC2-deficient Cells
Todeterminewhetherimmortalized621-101andclonal621-327
cells retained the functional consequences of TSC2 loss, protein
levels of tuberin and hamartin and several relevant mTOR effector
proteins were examined by Western blot analysis (Figure 1D).
Tuberin and hamartin protein levels were dramatically reduced in
both cell lines and the level of phospho-S6 (S235) was markedly
elevated. Levels of PDGFR-b and phospho-Akt (S473) were
decreased in TSC2-deficient cells compared to TSC-expressing
HEK293T cells. These signaling changes are in agreement with
previous findings in LAM cells, specifically that a TSC2 loss or
mutation leads to disruption of the tuberin-hamartin heterodimer
resulting in activation of the mTOR signaling pathway, and
dysregulation of S6K1 activation. Genomic DNA sequencing of
621-327 cells confirmed the nucleotide change G1832A in TSC2
cDNA on chromosome 16 (Figure S3), which results in an
Arg611Gln missense mutation, and loss of heterozygosity of the
TSC2 allele containing the wild-type residue (G).
Figure 2. Development of a quantifiable LAM/TSC animal model system. A. SPECT/CT imaging of NCr nu/nu mice 4 weeks after inoculation
of 621-327 cells by intravenous injection (left), intrapulmonary injection (middle), and intratracheal instillation (right). MIP = maximal intensity
projection; T = thyroid; S = stomach; B = bladder. Arrows indicate tumors confirmed after animal sacrifice. Scale bars=1 cm. *Two of four mice died
immediately after direct lung injections. {One mouse showed radiotracer uptake at week 4; others varied from week 8 to week 20. B. SPECT/CT
imaging (MIP) of a single mouse preinoculation (Day 0) and at varying times after intratracheal delivery of 621-327 cells. T = thyroid; S = stomach;
B = bladder. Arrows indicate tumors. Scale bars=1 cm. C. Kinetics of tumor growth measured using SPECT. Shown is %ID/mm
3*10
25 (mean 6 SD) in
6 tumors per mouse for n=3 mice over time.
doi:10.1371/journal.pone.0038589.g002
SPECT/CT Model of LAM/TSC
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Orthotopic Mouse Models
LAM is an unusual disease because the tumor cells have a benign
histological phenotype, but also have metastatic potential. To
determine whether TSC2-deficient 621-327 cells are capable of
disseminating and metastasizing in vivo, we administrated cells into
mice byintravenous injection, direct lung injection, orintratracheal
instillation.Interestingly,similartumorcelldepositionpatternswere
seen (Figure 2A), demonstrating that the TSC2-deficient cells in vivo
retained tumorigenicity and were disseminated systemically,
although the tumor take rate and latency varied in different
administrations. Intravenous administration of cells into athymic
NCr nu/nu mice resulted in a long latency and low take rate, with
tumors also trending toward a smaller size compared with other
modes of administration (Figure 2A). Direct needle injection of cells
into the lung resulted in distant tumor growth, but also high
mortality. Delivery of 621-327 cells via intratracheal instillation
resulted in tumor growth in 16 of 16 animals, short latency,
widespread dissemination, and relatively large tumors.
The kinetics of tumor spread from the lung to the body is shown
in Figure 2B. By day 2, signal in the lung was equivocal, likely due
to respiratory motion (discussed below). Surprisingly, within 1
week of intratracheal administration, distinct radiotracer accumu-
lation could be seen in the neck, axilla, groin region, right and/or
left flanks, and lung (sagittal) in SPECT/CT images (Figures 2A
and 2B, Video S1). Radiotracer uptake was also seen in the
thyroid, salivary glands, and stomach, as endogenous NIS is
expressed in these tissues.
Tumor size measured by
99mTcO4
- uptake was linearly propor-
tionaltothatmeasuredexvivousingcalipers,althoughconsistently2-
fold larger (Figure S1). From weeks 1 to 3 after intratracheal
administration,TSC2-deficienttumorsincreasedinsize.Fromweek
4onward,tumorsizewasrelativelyconstant,andoccasionallytumors
atweek4wereslightlysmallerthaninweek3(Figures2Band2C).To
date, after analysis of 347 tumors in 55 animals, none have fully
regressed afterpeaking at week 3 (data not shown).
Resection of tissue with high radiotracer uptake (Figure S2)
revealedapatternconsistentwithlymphaticorhematogenousspread
from the lung to lymph node basins. Indeed, histopathological
Figure 3. Lymph node metastasis and invasion by TSC2-deficient cells. A. Normal lymph node (LN; top row) and lymph node identified by
GFP and NIS expression (bottom row) 4 weeks after intratracheal administration of 621-327 cells. Left column shows in vivo color video image. Right
columns show same nodes ex vivo after resection, placement on black paper, and imaging using color video, GFP fluorescence, and SPECT/CT,
respectively. Scale bars=1 mm. B. Hematoxylin and eosin (H&E) staining of frozen sections from normal (top row) and tumor-infiltrated (bottom row)
lymph nodes 2 weeks after intratracheal administration of 621-327 cells. Dotted rectangle inset = higher magnification. Consecutive tissue sections
were also stained with anti-GFP antibody. Scale bars=50 mm. C. H&E staining of paraffin-embedded, tumor-infiltrated lymph nodes at 15 weeks post-
administration of 621-327 cells. Dotted rectangle inset = higher magnification. Scale bars=50 mm.
doi:10.1371/journal.pone.0038589.g003
SPECT/CT Model of LAM/TSC
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administration revealed NIS2/GFP-expressing tumor deposits
within lymph nodes (Figure 3A). Early tumor nodules were often
seenwithinsemi-encapsulatedstructuresinlymphnodes(Figure3B).
By weeks 3 to 4, most lymph nodes analyzed were completely
obliterated by the tumor cells with abundant or medium cytoplasm
(arrowhead).Interestingly,by15weekspostinoculation,sometumor
cells developed a smooth muscle cell morphology, and some lymph
nodes developedcystic orfluid-filled structures, although thesecysts
are not histologically identical to those observed in human LAM
(Figure3C).TheweakSPECTsignalmeasuredinlivingmouselungs
(Figure 2A), and the strong signal seen after sacrifice (Figure 4A)
suggest that the signal-to-noise ratio in the lungs was significantly
degraded by respiratory motion.
Formation of Pulmonary Abnormal Nodules in the Lungs
LAM is characterized by abnormal proliferation of smooth
muscle like cells, leading to destruction of the lung architecture
and formation of pulmonary cysts. To track the proliferation and
differentiation of TSC2-deficient cells in the lung, we monitored
and examined pathological changes of the mouse lungs at variable
time points for half a year. Analysis of resected specimens revealed
widespread tumor deposition and histopathological changes
(Figures 4A and 4B). At early time points, the tumor cells
appeared in small clusters adjacent to the lymphatic walls in the
lungs, gathering against the thin wall of bronchioles, in capillary
vessels, and in lymphatics (Figure 4A). Subsequently, pulmonary
nodules of different sizes were formed in mouse lungs (Figures 4B
and 4C). TSC2-deficient cells typically proliferated interstitially,
between blood vessels and alveoli. Thin walled microscopic cystic
areas were seen surrounding the tumor nodules (Figure 4C). Of
note, there was considerable heterogeneity in the lungs of the
mice, with some areas of the lung resembling the normal controls.
Molecular and Genetic Characterization of TSC2-deficient
Cells in Systemic Tumors
Immediately after SPECT/CT imaging at weeks 1, 2, 3, and 4
postinoculation, the major organs (lungs, heart, liver, spleen,
kidneys) and lymph nodes were collected and dissected. To
confirm that these cells were of human origin, we performed a
nested polymerase chain reaction (PCR) using human TSC2 exon
17-specific primers and purified genomic DNA as templates.
Because they were derived from a LAM-associate AML, the 621-
327 cells have a specific TSC2 mutation (Figure S3), which does
not occur in mouse cells. After DNA sequencing of PCR products,
Figure 4. Proliferation and pathogenesis of TSC2-deficient cells: pulmonary LAM like-nodules and cysts. A. Ex vivo SPECT/CT imaging
and antibody and H&E staining of lung. Resected whole lungs (left column) from LAM/TSC-bearing mice (top row) or control mice (bottom row) at 2
weeks postadministration of 621-327 cells. Scale bar=1 mm. Also shown are H&E staining (middle column) and anti-GFP antibody staining (right
column) of frozen sections from lungs at 4 weeks postadministration of 621-327 cells. Scale bars=50 mm. B. H&E staining of paraffin-embedded lung
tissue 15 weeks postadministration of 621-327 cells (top row) at low (top left) and high (top right and bottom row of dotted rectangles)
magnification. Scale bars=50 mm. C. Same as (B) except frozen sections at 26 weeks postadministration of 621-327 cells (left) with anti-human NIS
antibody staining (right). Scale bars=50 mm.
doi:10.1371/journal.pone.0038589.g004
SPECT/CT Model of LAM/TSC
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the lungs, kidneys, and lymph nodes (Figure S4).
Estrogen Enhances TSC2-deficient Cell Dissemination
and Growth in Male Mice
LAM occurs almost exclusively in women, with onset usually
during the childbearing years, which suggests that estrogen may
play a role in disease progression. To measure the effect of
estrogen, we implanted male and female mice with estradiol pellets
or placebo pellets 7 to 10 days before inoculation of tumor TSC2-
deficient cells. When assessed at 4 weeks, the 621-327 cells had a
much lower initiation and growth rate in male mice, and lower
overall radiotracer accumulation, which was partially corrected by
estradiol supplementation (Figure 5). Significant radiotracer
uptake was seen in female mice implanted with either estradiol
or placebo, suggesting that endogenous levels of estrogen in female
mice are sufficient for tumor initiation and proliferation.
Quantifying Drug Efficacy in Mice Bearing TSC2-deficient
Tumors
We next investigated whether this orthotopic model would
prove useful in quantifying tumor response to drug treatment. We
confirmed that rapamycin does not affect
99mTcO4
- uptake by NIS
(Figure S5A and B). Two weeks postimplantation, tumor-bearing
mice with a similar baseline of tumor burden and tumor size were
treated daily for 4 weeks with intraperitoneal injection of either 8-
mg/kg rapamycin or phosphate buffered saline (n=4 mice per
group). Tumor size and location were quantified by SPECT/CT
every other week. As shown in Figure 6A and B, mice treated with
rapamycin for at least 4 weeks exhibited a statistically significant
decrease in tumor uptake of radiotracer, which rebounded to
pretreatment levels 2 weeks after drug treatment was stopped.
Mice sacrificed at the end of this experiment showed no significant
difference in apoptosis (Figure S6A) or proliferation (Figure S6B)
between rapamycin treated and untreated tumors, confirming the
stability of the tumor mass after treatment ended.
Figure 5. The effect of sex and exogenous estrogen on TSC2-deficient tumor growth. Female (left) or male (right) mice were implanted
with 0.18 mg 17ß-estradiol pellets or control placebo pellets subcutaneously. Ten days later, 621-327 cells were administered intratracheally and
tumors quantified every other week by SPECT/CT. Shown are the results after 4 weeks of hormone treatment. T = thyroid; S = stomach; B = bladder.
Arrows indicate tumors. Scale bars =1 cm. +/2 =0.3–1.4; + =1.5 - 2.5; ++ =2.6–3.7; +++ = $3.8%ID/mm
3 (610
25).
doi:10.1371/journal.pone.0038589.g005
SPECT/CT Model of LAM/TSC
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TSC2-deficient cells, exhibiting loss of TSC2 and hyperactiva-
tion of the mTORC1 signaling pathway, can proliferate and
‘‘metastasize,’’ yet lack many features of malignant transformation.
Angiomyolipomas and LAM cells from patients with sporadic
LAM are histologically identical and consistent with the hypothesis
that these diseases share common genetic and pathogenetic
mechanisms [33,34]. Unfortunately, TSC genetic mouse models
[35,36] and other TSC models [37] do not develop lesions that
resemble human pulmonary LAM [38].
The isolation of homogeneous TSC2-deficient cells is critical for
developing robust and reliable animal models, yet has been
challenging. Recently, two TSC2-null cell lines (TSC2
2/2,
TSC2
2/meth) were isolated and characterized [23,24]. Despite
different genetic mutations, both TSC2
2/2 and TSC2
2/meth
smooth muscle-like cells shared proliferative and biochemical
characteristics, including a requirement for epidermal growth
factor (EGF), which cannot be replaced by insulin like-growth
factor 1(IGF1) [23,39]. In contrast, some human TCS2-deficient
cells (e.g., 621-327) do not require supplemental EGF in cell
culture medium for proliferation. Interestingly, the human TSC2-
deficient, non-EGF requiring cells we obtained displayed tumor-
igenicity, are capable of disseminating from the lung to lymph
nodes in vivo, and developed abnormal nodules in the lungs. To the
best of our knowledge, this is the first time that a homogeneous
LAM cell line capable of recapitulating some of the features of
human LAM/TSC in animals has been successfully obtained from
an angiomyolipoma with TSC2 gene mutations.
The orthotopic model we describe, harboring inactivation of
both alleles of TSC2, recapitulated several features of LAM. 621-
327 cells were able to traverse the lung epithelium and to travel to
distant tissues. Tumors in the lungs often had a morphology
resembling smooth muscle cells and cystic structures were often
present (Figure 3C). The migration of LAM cells to the lungs and
lymphatics is one of the disease’s most distinctive characteristics.
We found that 621-327 cells translocated from the lung to distinct
lymph node basins very rapidly (within days). Although recent
evidence suggests that human LAM might result in chyle-filled
lymphangioleiomyomas of the axial lymphatics [4,5], it should be
noted that our animal model appears to display less central
lymphatic involvement than expected. Nevertheless, it should now
be possible to quantify the contribution of VEGF-D and lymphatic
endothelial cells to this process. While many tumor models have
focused on blood capillary angiogenesis, this model may permit
the elucidation of basic mechanisms underlying lymph node
migration and tumor-initiated lymphangiogenesis.
Orthotopic tumor models tend to better mimic the vascular,
lymphatic, and stromal microenvironment of human tumors;
therefore, they offer theoretical advantages over subcutaneous
xenografts. Because the model we describe requires margination of
cells across the lung epithelium, and displays preferential homing to
a variety of tissues and organs, it will likely prove useful in
understandingthemolecularmechanismsunderlyingthesedifferent
Figure 6. Quantitation of LAM/TSC tumor response to drug treatment. A. Typical SPECT/CT images of mice treated with rapamycin or
vehicle for 4 weeks (i.e., 6 weeks after intratracheal administration of 621-327 cells). T = thyroid; S = stomach; B = bladder. Arrows indicate tumors.
Scale bars=1 cm. B.
99mTc-pertechnetate uptake in LAM/TSC tumors before, during, and after treatment with rapamycin or vehicle control. 621-327
cells were administered intratracheally at time=0. Rapamycin treatment was during weeks 2 to 6. Mice were followed an additional 2 weeks off drug.
doi:10.1371/journal.pone.0038589.g006
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tumor establishment, and the ability of estrogen to slightly increase
tumor number and size in male mice. These findings are consistent
with those from an Eker rat model [40,41], as well as collective
studies showing that LAM cell metastasis may be modulated by
VEGF-D, matrix metalloproteinases, extracellular matrix, and
estradiol [42,43,44,45]. A proposed multistep model of lymphatic
andestrogen-associatedmetastasisofLAMprogenitorcellstolymph
nodes, kidneys, and lungs was recently proposed [46].
A key feature of our model, with potential application to many
other human tumor syndromes, is the use of SPECT to quantify
tumorlocationandcellnumberinlivinganimals.Itshouldbenoted
that initial optimization of the model would not have been possible
without SPECT because the tumors were small and looked very
similartolymphnodes(Figure3A),whichwerenotvisiblebyCT.The
use of the radioactive pertechnetate anion over iodide is advanta-
geousintermsofcostandlogistics,withtheformerbeingnonvolatile,
readily available, and inexpensive. Although we used CT for
anatomical referencing, future use of magnetic resonance imaging
(MRI)willreduceoverallradiationexposureandimprovesofttissue
contrast.RespiratorygatingoftheSPECTsignalshouldalsoimprove
detectability in the lung. Co-expression of GFP provides a
convenient, nonradioactive surrogate for NIS expression, although
this was not employed in this study for full body imaging due to the
high absorptionand scatter of visible light.
The new model we describe, however, has significant limita-
tions. Secondary mutations in the originating cell line may have
occurred during passage. The location of cellular metastases does
not match exactly the distribution seen in human LAM and TSC.
For example, lymph node involvement is more peripheral in our
model, and more central in LAM. After an initial burst of
exponential growth, tumors stabilized in size for long periods of
time. Whether this is due to the incompletely suppressed immune
system of athymic NCR nu/nu mice is currently unknown.
Despite these limitations, from a practical standpoint, this novel
animal model may prove useful in testing new drugs, and more
importantly, drug combinations for the treatment of LAM/TSC,
allowing the kinetics of tumor development and metastasis to be
monitored over time. Recently, the mTOR inhibitor everolimus
was approved for the treatment of slow-growing TSC tumors in
the CNS [47], and its predecessor sirolimus was shown to
modulate AML and LAM [48,49]. However, tumor volume
reduction required months of continuous treatment and the
tumors regrew upon discontinuation of the treatment. A SPECT/
CT model of LAM/TSC will permit quantifiable in vivo testing of
drug combinations, and if combined with an in vitro prescreen,
could result in an efficient, cost-saving, high-throughput drug-
testing platform. The model also provides a platform for
developing drugs that interfere with various steps in the
progression of LAM/TSC. For example, administration of drugs
preinoculation and up to 1 week postinoculation could target cell
margination and metastasis. Drugs given from weeks 1 to 3 could
target tumor cell proliferation, and drugs give from week 4 onward
could target established tumors.
Supporting Information
Figure S1 Correlation of tumor size measured by
SPECT (ordinate) and calipers (abscissa).
(TIFF)
Figure S2 SPECT/CT imaging of tumor mice (in vivo)
and resected lymph nodes (ex vivo). Two weeks after tumor
inoculation, tumor bearing mice (in vivo) and dissected lymph
nodes (ex vivo) were scanned with SPECT/CT. Lymph nodes
exhibiting high radiotracer uptake and normal control lymph
nodes were resected.
(TIFF)
Figure S3 Genetic characterization of 621-327 cells.
Detection of the known TSC2 mutation (arrows; nucleotide
change G1832A in TSC2 cDNA or G26266A in exon 17 on
chromosome 16), which results in an Arg611Gln missense
mutation.
(TIFF)
Figure S4 Molecular and genetic characterization of
tumor cells in vivo. The characteristic G1832A TSC2 exon
17 mutation (arrows) from human 621-327 cells was found within
the mouse lymph nodes (LN), lung, and kidney. The mutation
(arrows; nucleotide change G1832A in TSC2 cDNA or G26266A
in exon 17 on chromosome 16) results in an Arg611Gln missense
mutation, and the fact that no wild-type allele is detected reflects
loss of heterozygosity of the TSC2 allele containing the wild-type
residue (G).
(TIFF)
Figure S5 Effect of rapamycin on radiotracer uptake of
NIS in vitro. Conditions were (1) preincubate with 10 nM
rapamycin for 24 h then 250 mCi
99mTcO4
- for 1 h prior to
measurement, (2) preincubate with 10 nM rapamycin for 1 h then
250 mCi
99mTcO4
- for 1 h prior to measurement, and (3) Control
with no rapamycin then 250 mCi
99mTcO4
- for 1 h prior to
measurement. A) Numerical values (%ID/mm
3610
25; mean 6
S.D.) and B) representative planar radioscintigraphic imaging of
cell wells.
(TIFF)
Figure S6 Apoptosis and cell proliferation of lung
tumors 2 w after rapamycin treatment. A. In situ apoptosis
detection of lung tissues counterstained with Methyl Green. The
frozen sections from rapamycin-treated or vehicle-treated lungs
(top row), and the normal lung treated with TACS
H-Nuclease for
positive control (bottom left) and normal lung (normal control,
bottom right). Arrow indicates an apoptotic cell. Scale
bars=50 mm. B. Detection of the cell proliferation marker Ki-67
in the lungs. Hematoxylin and eosin (H&E) staining of frozen
sections from rapamycin or vehicle-treated lungs (top row). The
consecutive tissue sections were also stained with Ki-67 antibody
(bottom row). Scale bars=50 mm.
(TIFF)
Video S1 In Vivo whole body tracking of LAM/TSC
tumors by SPECT/CT. 360u rotation of a 3-D SPECT/CT
reconstruction of a mouse 4 weeks after intratracheal administra-
tion of 621-327 cells. T = thyroid; S = stomach; B = bladder.
Arrows indicate tumors.
(MOV)
Method S1
(DOC)
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